BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 33743542)

  • 21. Up-Regulation of Follistatin-Like 1 By the Androgen Receptor and Melanoma Antigen-A11 in Prostate Cancer.
    Su S; Parris AB; Grossman G; Mohler JL; Wang Z; Wilson EM
    Prostate; 2017 Apr; 77(5):505-516. PubMed ID: 27976415
    [TBL] [Abstract][Full Text] [Related]  

  • 22. High placenta-specific 1/low prostate-specific antigen expression pattern in high-grade prostate adenocarcinoma.
    Ghods R; Ghahremani MH; Madjd Z; Asgari M; Abolhasani M; Tavasoli S; Mahmoudi AR; Darzi M; Pasalar P; Jeddi-Tehrani M; Zarnani AH
    Cancer Immunol Immunother; 2014 Dec; 63(12):1319-27. PubMed ID: 25186610
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Gene expression of MAGE-A3 and PRAME tumor antigens and EGFR mutational status in Taiwanese non-small cell lung cancer patients.
    Pan SH; Su KY; Spiessens B; Kusuma N; Delahaye NF; Gruselle O; Myo A; de Creus A; Louahed J; Chang GC; Yu SL; Yang PC
    Asia Pac J Clin Oncol; 2017 Oct; 13(5):e212-e223. PubMed ID: 27519286
    [TBL] [Abstract][Full Text] [Related]  

  • 24. STEAP1 protein overexpression is an independent marker for biochemical recurrence in prostate carcinoma.
    Ihlaseh-Catalano SM; Drigo SA; de Jesus CM; Domingues MA; Trindade Filho JC; de Camargo JL; Rogatto SR
    Histopathology; 2013 Nov; 63(5):678-85. PubMed ID: 24025158
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Correlation between the high expression levels of cancer-germline genes with clinical characteristics in esophageal squamous cell carcinoma.
    Chen X; Wang L; Yue D; Liu J; Huang L; Yang L; Cao L; Qin G; Li A; Wang D; Wang M; Qi Y; Zhang B; van der Bruggen P; Zhang Y
    Histol Histopathol; 2017 Aug; 32(8):793-803. PubMed ID: 27868181
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Overexpression of Cdc20 in clinically localized prostate cancer: Relation to high Gleason score and biochemical recurrence after laparoscopic radical prostatectomy.
    Mao Y; Li K; Lu L; Si-Tu J; Lu M; Gao X
    Cancer Biomark; 2016; 16(3):351-8. PubMed ID: 26889981
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Expression of MAGE-A3 in intrahepatic cholangiocarcinoma and its precursor lesions.
    Tsuneyama K; Sasaki M; Shimonishi T; Nakanuma Y
    Pathol Int; 2004 Mar; 54(3):181-6. PubMed ID: 14989741
    [TBL] [Abstract][Full Text] [Related]  

  • 28. PPM1D as a novel biomarker for prostate cancer after radical prostatectomy.
    Jiao L; Shen D; Liu G; Jia J; Geng J; Wang H; Sun Y
    Anticancer Res; 2014 Jun; 34(6):2919-25. PubMed ID: 24922655
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Expression of MAGE-A3/6 in primary breast cancer is associated with hormone receptor negative status, high histologic grade, and poor survival.
    Ayyoub M; Scarlata CM; Hamaï A; Pignon P; Valmori D
    J Immunother; 2014; 37(2):73-6. PubMed ID: 24509169
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prospective assessment of a gene signature potentially predictive of clinical benefit in metastatic melanoma patients following MAGE-A3 immunotherapeutic (PREDICT).
    Saiag P; Gutzmer R; Ascierto PA; Maio M; Grob JJ; Murawa P; Dreno B; Ross M; Weber J; Hauschild A; Rutkowski P; Testori A; Levchenko E; Enk A; Misery L; Vanden Abeele C; Vojtek I; Peeters O; Brichard VG; Therasse P
    Ann Oncol; 2016 Oct; 27(10):1947-53. PubMed ID: 27502712
    [TBL] [Abstract][Full Text] [Related]  

  • 31. STEAP1 is overexpressed in prostate cancer and prostatic intraepithelial neoplasia lesions, and it is positively associated with Gleason score.
    Gomes IM; Arinto P; Lopes C; Santos CR; Maia CJ
    Urol Oncol; 2014 Jan; 32(1):53.e23-9. PubMed ID: 24239460
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Examination of CK2α and NF-κB p65 expression in human benign prostatic hyperplasia and prostate cancer tissues.
    Qaiser F; Trembley JH; Sadiq S; Muhammad I; Younis R; Hashmi SN; Murtaza B; Rector TS; Naveed AK; Ahmed K
    Mol Cell Biochem; 2016 Sep; 420(1-2):43-51. PubMed ID: 27435858
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impact of the EpCAM expression on biochemical recurrence-free survival in clinically localized prostate cancer.
    Benko G; Spajić B; Krušlin B; Tomas D
    Urol Oncol; 2013 May; 31(4):468-74. PubMed ID: 21514185
    [TBL] [Abstract][Full Text] [Related]  

  • 34. MAGE-A3 immunotherapeutic as adjuvant therapy for patients with resected, MAGE-A3-positive, stage III melanoma (DERMA): a double-blind, randomised, placebo-controlled, phase 3 trial.
    Dreno B; Thompson JF; Smithers BM; Santinami M; Jouary T; Gutzmer R; Levchenko E; Rutkowski P; Grob JJ; Korovin S; Drucis K; Grange F; Machet L; Hersey P; Krajsova I; Testori A; Conry R; Guillot B; Kruit WHJ; Demidov L; Thompson JA; Bondarenko I; Jaroszek J; Puig S; Cinat G; Hauschild A; Goeman JJ; van Houwelingen HC; Ulloa-Montoya F; Callegaro A; Dizier B; Spiessens B; Debois M; Brichard VG; Louahed J; Therasse P; Debruyne C; Kirkwood JM
    Lancet Oncol; 2018 Jul; 19(7):916-929. PubMed ID: 29908991
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Overexpression of LAPTM4B-35: a novel marker of poor prognosis of prostate cancer.
    Zhang H; Wei Q; Liu R; Qi S; Liang P; Qi C; Wang A; Sheng B; Li L; Xu Y
    PLoS One; 2014; 9(3):e91069. PubMed ID: 24651764
    [TBL] [Abstract][Full Text] [Related]  

  • 36. MAGE-A3 is a prognostic biomarker for poor clinical outcome in cutaneous squamous cell carcinoma with perineural invasion via modulation of cell proliferation.
    Chen A; Santana AL; Doudican N; Roudiani N; Laursen K; Therrien JP; Lee J; Felsen D; Carucci JA
    PLoS One; 2020; 15(11):e0241551. PubMed ID: 33227008
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Activation of melanoma antigen tumor antigens occurs early in lung carcinogenesis.
    Jang SJ; Soria JC; Wang L; Hassan KA; Morice RC; Walsh GL; Hong WK; Mao L
    Cancer Res; 2001 Nov; 61(21):7959-63. PubMed ID: 11691819
    [TBL] [Abstract][Full Text] [Related]  

  • 38. MAGE-A family is involved in gastric cancer progression and indicates poor prognosis of gastric cancer patients.
    Lian Y; Sang M; Gu L; Liu F; Yin D; Liu S; Huang W; Wu Y; Shan B
    Pathol Res Pract; 2017 Aug; 213(8):943-948. PubMed ID: 28647208
    [TBL] [Abstract][Full Text] [Related]  

  • 39. PSCA, Cox-2, and Ki-67 are independent, predictive markers of biochemical recurrence in clinically localized prostate cancer: a retrospective study.
    Kim SH; Park WS; Park BR; Joo J; Joung JY; Seo HK; Chung J; Lee KH
    Asian J Androl; 2017; 19(4):458-462. PubMed ID: 27232854
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Androgen receptor expression in prostatic intraepithelial neoplasia and cancer.
    Sweat SD; Pacelli A; Bergstralh EJ; Slezak JM; Bostwick DG
    J Urol; 1999 Apr; 161(4):1229-32. PubMed ID: 10081875
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.